BIIB
Biogen Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Market Cap: 31.6 Billion
Primary Exchange: NASDAQ
Website: https://www.biogen.com/
Shares Outstanding: 145 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 2544 trading days
From: 2015-03-20 To: 2024-03-07
Lowest Point:
Prevail Therapeutics Proposes IPO Terms
via: SeekingAlpha at 2019-06-13 07:46:25:000
Quick Take Prevail Therapeutics ( PRVL ) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Merger Arbitrage Mondays - Insider Purchase By A Director Of Mellanox Technologies
via: SeekingAlpha at 2019-06-11 07:05:09:000
Merger activity increased last week with six new deals announced and one pending deal closing. There was an interesting insider purchase at Mellanox Technologies (MLNX) last week that we wrote about yesterday. Director Steve Sanghi acquired 20,000 shares of this semiconductor company, p… read more...
How To Find Undervalued Stocks In The Healthcare Sector
via: SeekingAlpha at 2019-06-10 12:10:41:000
The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts … read more...
Time Is Brain: Bioxytran's Tissue Oxygenation Therapy May Breathe New Life Into Stroke Victims
via: SeekingAlpha at 2019-06-09 17:30:33:000
Introduction The stroke market is ripe for the taking. Existing treatments are limited, and the unmet medical need is great. In contrast to breakthroughs in many diseases over the past two decades, stroke treatment, especially from drugs, has had minimal improvement for the past 23 ye… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|